List of Excipients in Branded Drug SODIUM NITROPRUSSIDE IN 0.9% SODIUM CHLORIDE

Generic Drugs Containing SODIUM NITROPRUSSIDE IN 0.9% SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Slate Run Pharmaceuticals LLC	sodium nitroprusside in 0.9% sodium chloride	70436-207	SODIUM CHLORIDE
Slate Run Pharmaceuticals LLC	sodium nitroprusside in 0.9% sodium chloride	70436-207	WATER

What are the Most Frequently-Used Excipients in SODIUM NITROPRUSSIDE IN 0.9% SODIUM CHLORIDE?

# Of NDCs	Excipient
1	SODIUM CHLORIDE
1	WATER

Sodium Nitroprusside in 0.9% Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 2, 2026

Sodium nitroprusside in 0.9% sodium chloride is a differentiated ready-to-use intravenous product rather than a novel active-ingredient opportunity. The commercial value is concentrated in formulation execution: light protection, chemical stability, container compatibility, particulate control, low preparation burden, and reliable hospital supply. The active ingredient is long established, and the core sodium nitroprusside-saline composition has limited prospects for broad composition-of-matter protection. Durable value is more likely to come from manufacturing controls, ready-to-administer packaging, contractual supply, device integration, and narrowly drafted formulation or process patents.

What is sodium nitroprusside in 0.9% sodium chloride used for?

Sodium nitroprusside is a rapidly acting intravenous vasodilator used to reduce blood pressure and control cardiac preload and afterload in acute-care settings. The drug is administered by continuous infusion, with dose titration based on blood pressure and hemodynamic response [1].

A 0.9% sodium chloride presentation is a premixed, ready-to-use formulation. It removes the need for pharmacy dilution from a concentrated vial and may reduce preparation errors, handling time, and exposure to light during compounding.

Typical target settings include:

• Intensive-care units
• Operating rooms
• Emergency departments
• Cardiovascular surgery
• Acute hypertensive crises
• Controlled reduction of arterial pressure during surgery
• Acute heart-failure or afterload-reduction protocols

The commercial proposition is operational rather than therapeutic. Sodium nitroprusside has a short half-life and requires continuous monitoring, limiting its use to settings with infusion pumps and trained staff.

What excipients are used in sodium nitroprusside 0.9% sodium chloride injection?

The formulation is generally composed of sodium nitroprusside, sodium chloride, and Water for Injection. The saline vehicle is both an excipient and a functional diluent.

Component	Primary function	Key development issue
Sodium nitroprusside	Active vasodilator	Light and chemical degradation; cyanide-related toxicity at excessive exposure
Sodium chloride, 0.9%	Isotonic vehicle and diluent	Sodium load, osmolality, chloride burden
Water for Injection	Solvent	Sterility, endotoxin, particulate control
Container and overwrap	Product protection	Light transmission, adsorption, extractables, leachables

Most commercial presentations do not require a buffer, antioxidant, antimicrobial preservative, surfactant, or chelating agent. Avoiding those excipients reduces toxicology, compatibility, and regulatory complexity.

The formulation strategy should preserve a simple composition unless stability data demonstrate a need for pH adjustment or another stabilizing excipient. Any added excipient creates a new regulatory burden and may reduce the commercial advantage of a familiar saline product.

Why does 0.9% sodium chloride create a commercial opportunity?

The main advantage is workflow simplification. Traditional sodium nitroprusside products have commonly been supplied as concentrated solutions requiring dilution before infusion, historically including dilution in 5% dextrose. A premixed saline bag provides a standardized concentration and eliminates a pharmacy preparation step [1, 2].

Key commercial benefits include:

1. Reduced compounding labor.
2. Lower risk of dilution or labeling errors.
3. Faster deployment in urgent-care environments.
4. Better standardization across hospital protocols.
5. Potentially lower handling exposure to a light-sensitive solution.
6. Compatibility with institutions that prefer saline-based infusions.

The product does not eliminate clinical monitoring. It remains a high-risk infusion requiring an infusion pump, close blood-pressure monitoring, and attention to cumulative cyanide and thiocyanate exposure [1].

What formulation properties must a sodium nitroprusside saline product control?

Light protection

Sodium nitroprusside is light sensitive. Product labeling requires protection from light, and commercial packaging commonly uses an opaque overwrap or light-resistant secondary container [1]. The light barrier is a central product attribute and a potential source of defensible intellectual property.

Development work should measure:

• Assay loss under defined light exposure
• Formation of degradation products
• Light transmission through the bag, port, tubing, and overwrap
• Stability after removal from the overwrap
• Stability during simulated operating-room handling
• Compatibility with infusion sets and pump systems

A container that protects the bag but permits significant light exposure through the administration set may not provide complete product protection.

Chemical stability

The sponsor should establish stability across:

• Refrigerated storage
• Controlled room temperature
• Short-term temperature excursions
• In-use infusion periods
• Transport vibration and pressure
• Headspace and fill-volume variations

The commercial target is a shelf life that supports hospital inventory management, not merely a short pharmacy-use period. A longer labeled shelf life can improve purchasing and reduce product waste.

Container compatibility

Flexible polyolefin bags, multilayer films, elastomeric ports, and administration sets should be evaluated for:

• Adsorption of sodium nitroprusside
• Degradation caused by contact surfaces
• Extractables and leachables
• Drug concentration changes over time
• Port and tubing compatibility
• Container closure integrity
• Microbial ingress risk

The container system may be more important than the nominal excipient list. A formulation that is chemically acceptable in glass may behave differently in a polymeric bag.

Particulate and sterility performance

Because the product is administered intravenously, particulate control, sterility assurance, endotoxin limits, and visible inspection are central quality attributes. The formulation should avoid unnecessary ingredients that increase precipitation or interaction risk.

What formulation patents could protect sodium nitroprusside in 0.9% sodium chloride?

Broad claims covering sodium nitroprusside dissolved in 0.9% sodium chloride are likely to face significant prior-art challenges because the active ingredient, saline vehicle, injectable presentation, and light-protection requirements are longstanding concepts.

More credible claim categories include:

Patent target	Potential claim scope	Relative defensibility
Stabilized saline formulation	Narrow pH, concentration, impurity, or degradation limits	Moderate if supported by unexpected stability data
Light-protective container	Defined transmission limits and multilayer construction	Moderate
Ready-to-use bag	Specific concentration, fill volume, closure, and shelf life	Low to moderate
Administration system	Bag, opaque tubing, pump, and protective sleeve combination	Moderate
Manufacturing process	Controlled order of addition, oxygen control, sterilization, or aseptic filling	Moderate
Degradation control	Defined impurity profile after light or thermal challenge	Moderate
Clinical workflow	Reduced preparation steps or standardized infusion protocol	Usually weak as composition protection; possible method claims
Device-integrated delivery	Product packaged with dedicated light-protective infusion hardware	Moderate to strong if technically specific

The best patent program would combine formulation, container, process, and device claims. A single claim directed to “sodium nitroprusside in 0.9% sodium chloride” would be exposed to prior-art and obviousness attacks.

What data would strengthen a formulation patent?

Patent strength would improve if the sponsor could show a measurable technical effect, such as:

• A materially longer shelf life than conventional saline formulations
• Lower degradation under defined light exposure
• Lower impurity formation at elevated temperature
• Improved stability in a polymer bag compared with glass
• Reduced adsorption to tubing
• A specific overwrap or film achieving an unexpected transmission threshold
• A manufacturing sequence that produces a distinct impurity profile
• A lower-cost sterilization process that preserves assay and color

The claims should tie the technical result to measurable parameters. Generic claims based only on concentration, vehicle, or “protected from light” language are vulnerable.

What is the Orange Book status of sodium nitroprusside in 0.9% sodium chloride?

Sodium nitroprusside is an old active ingredient with generic injectable products. The relevant regulatory question is product-specific: whether a particular ready-to-use saline product is listed under a New Drug Application or approved through an Abbreviated New Drug Application, and whether any patents or regulatory exclusivities are listed for that product in the FDA Orange Book [3].

For an established generic injectable, the likely competitive structure is:

• No active-ingredient exclusivity
• Limited or no commercially meaningful Orange Book patent protection for the basic saline composition
• Potential ANDA competition
• Regulatory differentiation based on presentation, availability, and manufacturing reliability
• Patent value concentrated in later-issued formulation, container, process, or device claims

The FDA Orange Book should be reviewed product by product because listing status can change with supplements, transfers, discontinuations, or new patents [3]. A patent analyst should not infer protection from the existence of a product label alone.

When does sodium nitroprusside lose exclusivity?

The active ingredient has no practical remaining new-molecule exclusivity. Sodium nitroprusside was approved decades ago, and generic competition exists in injectable presentations [1, 3].

For a specific sodium nitroprusside-in-saline product, the relevant dates are:

Exclusivity or protection category	Commercial relevance
New chemical entity exclusivity	Not relevant to this old active ingredient
Orphan-drug exclusivity	Not generally associated with this product
Pediatric exclusivity	Product-specific and unlikely to define the market
Orange Book formulation patent	Must be verified by product and current listing
Process patent	May affect manufacturing but usually does not block all ANDA entry
Container or device patent	Can create a narrower market barrier
Trade-secret manufacturing know-how	May delay replication without formally blocking approval
Supply agreement	Can protect hospital accounts without creating legal exclusivity

The most realistic market-entry protection is operational. A supplier that can consistently deliver sterile, light-protected premixed bags may win contracts even without broad patent coverage.

How strong is the patent estate for sodium nitroprusside in saline?

The underlying patent estate is likely weak to moderate, depending on claim scope and technical data.

Weak areas

• Sodium nitroprusside as an active ingredient
• Sodium chloride as an injectable vehicle
• Basic ready-to-use dilution
• General light protection
• Conventional sterile filling
• Standard infusion-bag packaging

Stronger potential areas

• A validated low-degradation formulation across a defined pH range
• A multilayer light-barrier bag with quantified transmission performance
• A specific administration set that maintains stability through infusion
• A manufacturing process that limits oxygen or metal-catalyzed degradation
• A product with a demonstrated extended shelf life under challenging conditions
• Integrated packaging that prevents light exposure from storage through administration

Freedom-to-operate analysis should distinguish between patent infringement and regulatory approval. A process patent may not prevent a competing company from selling a product made by a different process. A device patent may block a particular delivery configuration while leaving the active formulation open.

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV challenge is relevant only when an ANDA applicant identifies a listed patent in the Orange Book and certifies that the patent is invalid, unenforceable, or not infringed under the Hatch-Waxman framework [4].

For sodium nitroprusside in saline, generic entry risks arise from:

• A competing ANDA for the same strength and dosage form
• A 505(b)(2) application with a different container, concentration, or administration system
• Hospital compounders or outsourcing facilities supplying alternative presentations
• Private-label supply from contract manufacturers
• Patent challenges directed at narrow formulation or packaging claims
• Product shortages that prompt institutional substitution

The likely entry pathway is an ANDA for a pharmaceutically equivalent injectable product. A 505(b)(2) pathway could be more relevant where the applicant seeks approval for a new ready-to-use configuration, novel infusion device, different vehicle, or new stability profile [5].

A first generic could obtain a commercial advantage through preferred hospital contracts even if no 180-day exclusivity is available. The strategic risk is therefore not limited to formal patent expiry.

What manufacturing and intellectual-property barriers affect market entry?

Manufacturing barriers

Sodium nitroprusside saline products require control over:

• Aseptic processing
• Light exposure during compounding and filling
• Oxygen exposure
• Solution pH
• Bag-film compatibility
• Sterilization strategy
• Container closure integrity
• Shipping temperature
• In-use stability
• Consistent fill volume and concentration

The product may be technically simple but operationally sensitive. A manufacturer with experience in sterile premixed bags has an advantage over a company that only has vial-filling capability.

Intellectual-property barriers

The most relevant IP categories are:

1. Formulation patents.
2. Container and film patents.
3. Light-protection systems.
4. Manufacturing-process patents.
5. Infusion-device patents.
6. Trade secrets covering impurity control and shelf-life performance.
7. Trademarks and hospital-contract positioning.

Trade secrets can be commercially important where the public label does not disclose the complete manufacturing process, oxygen controls, filling sequence, or packaging qualification strategy.

How does sodium nitroprusside in saline compare with concentrated vial products?

Attribute	Premixed 0.9% sodium chloride	Concentrated vial
Pharmacy preparation	Minimal	Requires dilution
Dosing standardization	High	Depends on dilution process
Light handling	Controlled by commercial packaging	Greater exposure during preparation
Storage volume	Larger	Smaller
Sodium or fluid burden	Depends on bag volume	Determined by final diluent
Hospital convenience	Higher	Lower
Manufacturing complexity	Higher	Lower
Packaging differentiation	Strong	More limited
Patent opportunity	Container, process, device	Formulation and process
Price premium potential	Moderate	Usually limited in generic markets

The premixed product can justify a higher unit price if it reduces pharmacy labor, preparation time, waste, and medication-error risk. The premium is constrained by the availability of low-cost concentrated products and by hospital purchasing policies.

What commercial opportunities exist beyond the basic saline bag?

Ready-to-administer critical-care portfolio

A manufacturer can position sodium nitroprusside with other premixed vasoactive or antihypertensive injections. Hospitals often value standardized packaging, common concentrations, and consolidated procurement.

Potential portfolio extensions include:

• Multiple fill volumes
• Standardized concentration options
• Pharmacy bulk packages where permitted
• Light-protective administration sets
• Emergency-department and operating-room configurations
• Pre-labeled products for automated dispensing systems

Contract manufacturing and private label

Sterile injectable capacity is constrained in many markets. A company with qualified bag-filling and light-protection capabilities could supply hospital systems, wholesalers, or private-label pharmaceutical companies.

Integrated infusion systems

The strongest differentiation may come from a product-device combination that maintains light protection from storage through infusion. The package could include:

• Light-resistant bag
• Opaque tubing
• Compatible pump channel
• Standardized concentration
• Electronic labeling or barcode configuration

Such a system may support device patents, workflow claims, and institutional contracts.

Geographic expansion

The United States, Europe, Japan, and other regulated markets require country-specific regulatory, labeling, and packaging compliance. Commercial expansion should account for:

• Local availability of sodium nitroprusside
• National reference-product requirements
• Sterile injectable registration standards
• Hospital procurement structures
• Language-specific warnings
• Pharmacopoeial requirements
• Local rules for ready-to-use admixtures

A formulation accepted in the United States may require additional stability, container, or compatibility data in other jurisdictions.

What regulatory issues determine commercial success?

FDA-approved labeling emphasizes controlled intravenous administration, light protection, dose titration, and monitoring for cyanide and thiocyanate toxicity [1]. The saline presentation must demonstrate pharmaceutical equivalence or an appropriate bridging strategy, depending on the approval pathway.

Key regulatory workstreams include:

• Assay and degradation-product specifications
• Sterility and bacterial endotoxin testing
• Particulate matter
• Container closure integrity
• Extractables and leachables
• In-use and infusion-set stability
• Photostability
• Shipping and temperature-excursion studies
• Comparative bioavailability or pharmaceutical-equivalence data where required
• Labeling for sodium content and administration precautions

A preservative-free, single-dose presentation is generally preferable for an intravenous emergency product. It reduces concerns about preservative exposure and simplifies hospital protocols.

What revenue exposure and market risks should investors assess?

Public sources do not provide a reliable product-specific revenue figure for every sodium nitroprusside saline presentation. Revenue analysis should therefore focus on market structure and purchasing dynamics rather than extrapolating from the active ingredient alone.

The main revenue drivers are:

• Number of approved competitors
• Hospital contract coverage
• Availability of concentrated alternatives
• Sterile injectable shortages
• Product discontinuations
• Bag sizes and concentration choices
• Wholesaler inventory
• Manufacturing reliability
• Pricing premiums for ready-to-use products

The principal risks are generic price erosion, low treatment volume, hospital formulary substitution, and supply interruptions. The strongest upside is a shortage-resistant, ready-to-use product with superior shelf life and dependable delivery.

What licensing deals could support commercialization?

Potential licensing structures include:

• License of a light-protective film or overwrap
• Contract manufacturing agreement for sterile bag filling
• Co-development with an infusion-pump manufacturer
• Private-label supply to a hospital distributor
• Regional rights for a ready-to-use injectable platform
• Technology transfer for photostability and container qualification
• Portfolio licensing covering multiple critical-care injectables

A license should define ownership of formulation improvements, packaging patents, process know-how, regulatory data, shortage allocation, change-control authority, and supply-failure remedies. For a mature active ingredient, the value of the transaction will depend more on manufacturing access and commercial execution than on the sodium nitroprusside molecule.

Key Takeaways

• Sodium nitroprusside in 0.9% sodium chloride is primarily a ready-to-use hospital workflow product.
• The core composition has limited prospects for broad patent protection because the active ingredient and saline vehicle are established.
• The most credible IP opportunities involve photostability, container systems, infusion compatibility, manufacturing controls, and extended shelf life.
• FDA labeling requires light protection, controlled infusion, and monitoring for toxicity [1].
• Generic entry risk is substantial because the active ingredient is old and injectable competition exists.
• Commercial value depends on sterile manufacturing capacity, product availability, hospital contracts, and reduced pharmacy preparation.
• A differentiated bag-plus-administration-set system may support stronger protection than the saline formulation alone.
• No meaningful new-molecule exclusivity should be expected.
• Revenue opportunity is strongest in ready-to-administer critical-care portfolios, private-label supply, and shortage-resistant procurement channels.

FAQs About Sodium Nitroprusside in 0.9% Sodium Chloride

Is sodium nitroprusside in saline preservative-free?

Commercial single-dose injectable presentations are generally formulated without antimicrobial preservatives. The applicable product label controls the exact inactive-ingredient disclosure [1].

Can sodium nitroprusside in 0.9% sodium chloride be protected with an antioxidant?

An antioxidant could be evaluated, but it would add compatibility, toxicology, and regulatory complexity. The preferred first strategy is usually container, oxygen-control, and light-protection optimization.

Does a ready-to-use sodium nitroprusside bag qualify for a new patent?

Possibly, but a broad claim covering the active ingredient in saline is vulnerable. Patentability is stronger where the product includes a demonstrated stability improvement, defined impurity control, specialized container, or integrated infusion system.

What is the main hospital advantage of the saline presentation?

It reduces dilution and labeling steps before infusion. That can lower preparation burden and improve concentration standardization in emergency and operating-room settings.

Can a competitor launch sodium nitroprusside in saline without infringing a container patent?

Potentially. A competitor may avoid infringement by using a different film, overwrap, administration set, filling process, or container configuration, subject to the actual patent claims and regulatory requirements.

References

1. U.S. Food and Drug Administration. (2023). Nitropress (sodium nitroprusside) injection, prescribing information. FDA.
2. DailyMed. (2024). Sodium nitroprusside injection product labeling. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed.: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2017). The Hatch-Waxman Amendments: Questions and answers. FDA.
5. U.S. Food and Drug Administration. (2023). 505(b)(2) applications. FDA.